#	Pagina
attuale pagina	/open-h2020/projects/211973/index.html

Opendata, web and dolomites

ENTRANCE SIGNED

Developing the iTOP kit: Empowering scientists with efficient intracellular delivery of biologicals in hard-to-manipulate cell types

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ENTRANCE project word cloud

Explore the words cloud of the ENTRANCE project. It provides you a very rough idea of what is the project "ENTRANCE" about.

interactive bv create move community drug marketing sharing stem tool merits wo2015028969 investments entry biomedical experiences active efficient ruo models generously inside leader rna diseases ntrans biomedically ambition genetic kit standard 2015 possibilities fte bioactive unprecedented unmet notoriously cells forecasted pipeline scientifically back forum accelerated innovative developers mammalian team immense dna manipulate primary significantly line itop instigate revolution molecules biomolecules scientific biologically technologies human market patented difficult 16 published proper combinations transfect latter entrance immortalized lines 2020 earn buzz empowering stimulate sme proteins expand sciences validated pace direct types extremely therapeutic journal underpin cell efficiency

Project "ENTRANCE" data sheet

The following table provides information about the project.

Coordinator	NTRANS TECHNOLOGIES BV Organization address address: UPPSALALAAN 8 city: UTRECHT postcode: 3584 CT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	https://www.ntranstechnologies.com/entrance/
Total cost	1˙514˙200 €
EC max contribution	1˙514˙200 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2017
Duration (year-month-day)	from 2017-09-01 to 2019-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	NTRANS TECHNOLOGIES BV NTRANS TECHNOLOGIES BV Organization address address: UPPSALALAAN 8 city: UTRECHT postcode: 3584 CT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	coordinator	1˙514˙200.00

Map

Project objective

NTrans Technologies BV has developed iTOP; a novel and extremely effective method to deliver highly relevant bioactive molecules (including DNA, RNA, active proteins, and their combinations) into mammalian cells. This includes the efficient delivery of such molecules inside the most biologically and biomedically relevant cell types (e.g. human primary and stem cells), which are notoriously difficult to manipulate. iTOP technology has been scientifically validated (published in the top scientific journal Cell in 2015) and patented (WO2015028969).

iTOP addresses the unmet need of researchers and drug developers to be able to transfect a range of biomolecules into biologically relevant cell models; in particular to study genetic diseases and to underpin results obtained with standard immortalized cell lines.

The ENTRANCE project includes the necessary steps towards market entry of the iTOP research-use-only (RUO) kit: The development of (i) an iTOP RUO kit and (ii) an iTOP on-line community as innovative marketing tool that will support proper use and stimulate efficient application of the technology. The ENTRANCE project will thus provide the scientific community access to the novel iTOP tool, facilitate direct access of iTOP kit users to the NTrans support team, and enable sharing of user experiences via an iTOP interactive forum.

ENTRANCE will instigate a revolution in biomedical sciences by empowering both researchers and drug developers to manipulate the most relevant cell types with unprecedented efficiency. This will allow the field to move forward at a significantly accelerated pace.

The iTOP RUO kit will generously earn back the investments within 4 years, and help to create a buzz around the merits and possibilities of the technology. The latter is of immense value to the SME forecasted to support 16 FTE by 2020, with the ambition to expand its product pipeline and become leader in technologies for delivery of therapeutic biomolecules into primary cells.

Deliverables

List of deliverables.
3.4b iTOP community platform completed	Websites, patent fillings, videos etc.	2020-03-24 11:33:03
1.5b First lot of sample kit produced	Demonstrators, pilots, prototypes	2020-02-27 15:22:05
1.3 Digital user manuals completed	Documents, reports	2020-02-27 15:21:52
3.5b Final version of the DMP	Documents, reports	2019-07-30 13:59:42
3.1b Report of the Mid-Term event	Documents, reports	2019-05-31 11:55:55
3.3a Dedicated web pages for ENTRANCE	Websites, patent fillings, videos etc.	2019-05-31 11:55:51
3.1a Report of the Kick-off Event	Documents, reports	2019-05-31 11:55:52
3.5a First version of DMP	Documents, reports	2019-05-31 11:56:04

Take a look to the deliverables list in detail: detailed list of ENTRANCE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENTRANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENTRANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination